Cortex to start fragile X, autism Phase II

COR will begin in May a double-blind, placebo-controlled U.S. Phase II trial of its Ampakine (CX516) AMPA glutamate receptor enhancer to treat fragile X syndrome and autism. The one-month trial will m...